問卷

TPIDB > Search Result

Search Result

篩選

List

27Cases

2025-09-01 - 2028-09-01

Phase I/II

Completed
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPK Pathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations
  • Condition/Disease

    Advanced or Metastatic Solid Tumors With RAS/MAPK Pathway Mutations

  • Test Drug

    DCC-3116

Participate Sites
4Sites

Recruiting4Sites

2020-01-06 - 2026-01-31

Phase III

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

2020-08-31 - 2027-12-31

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
11Sites

Recruiting11Sites

2020-12-14 - 2024-03-31

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Recruiting8Sites

2022-09-01 - 2025-12-31

Phase I

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Recruiting7Sites

Terminated1Sites

2022-11-01 - 2037-11-01

Others

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Not yet recruiting1Sites

Recruiting4Sites

2023-07-07 - 2026-07-31

Phase I

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

2021-05-01 - 2026-12-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2020-09-01 - 2026-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2020-09-01 - 2027-06-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting1Sites

Recruiting5Sites

1 2 3